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Abstract
Background: Kallikrein 6 (KLK6) is a newly identified member of the kallikrein family of secreted serine proteases that prior
studies indicate is elevated at sites of central nervous system (CNS) inflammation and which shows regulated expression
with T cell activation. Notably, KLK6 is also elevated in the serum of multiple sclerosis (MS) patients however its potential
roles in immune function are unknown. Herein we specifically examine whether KLK6 alters immune cell survival and the
possible mechanism by which this may occur.
Methodology/Principal Findings: Using murine whole splenocyte preparations and the human Jurkat T cell line we
demonstrate that KLK6 robustly supports cell survival across a range of cell death paradigms. Recombinant KLK6 was shown
to significantly reduce cell death under resting conditions and in response to camptothecin, dexamethasone, staurosporine
and Fas-ligand. Moreover, KLK6-over expression in Jurkat T cells was shown to generate parallel pro-survival effects. In
mixed splenocyte populations the vigorous immune cell survival promoting effects of KLK6 were shown to include both T
and B lymphocytes, to occur with as little as 5 minutes of treatment, and to involve up regulation of the pro-survival protein
B-cell lymphoma-extra large (Bcl-XL), and inhibition of the pro-apoptotic protein Bcl-2-interacting mediator of cell death
(Bim). The ability of KLK6 to promote survival of splenic T cells was also shown to be absent in cell preparations derived from
PAR1 deficient mice.
Conclusion/Significance: KLK6 promotes lymphocyte survival by a mechanism that depends in part on activation of PAR1.
These findings point to a novel molecular mechanism regulating lymphocyte survival that is likely to have relevance to a
range of immunological responses that depend on apoptosis for immune clearance and maintenance of homeostasis.
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Introduction
Kallikrein 6 (KLK6) is a secreted serine protease and member of
the largest contiguous cluster of serine proteases in the human
genome. In prior studies we have demonstrated elevated levels of
KLK6 occur in active MS lesions and in the serum of patients
experiencing a secondary progressive disease course. KLK6 levels
have also been shown to be present in infiltrating immune cells at
sites of CNS inflammation in animal models of MS and to be up
regulated in T cells with activation [1,2,3,4]. Additionally,
blocking KLK6 activity diminishes clinical and histological disease
as well as Th1 inflammatory responses in experimental autoim-
mune encephalomyelitis (EAE) [5], yet the role and mechanism of
action of KLK6 in immune function has not been previously
examined.
While best characterized for its ability to degrade extracellular
matrix factors including laminin, fibronectin and heat denatured
collagen [6,7], in addition to myelin proteins [1], KLK6 has also
been recently demonstrated to activate a subset of protease
activated receptors (PAR) [8,9,10,11]. PARs are G-protein
coupled transmembrane receptors that are uniquely activated by
proteolytic cleavage and well known to play key roles in driving
inflammatory responses. Of the four known PARs, KLK6 has
been shown to activate PAR1 in neurons and both PAR1 and
PAR2 in astrocytes triggering intracellular Ca
2+ flux and
differentially affecting both MAPK and AKT signaling pathways
[11]. KLK6 was also shown to activate PAR2 in HEK cells to
trigger Ca
2+ signaling and on aortic endothelial cells to mediate
relaxation [9]. Whether KLK6 induces signaling in lymphocytes
and the dependence of this on PAR has not been previously
addressed.
The physiological actions of PARs have perhaps been most
extensively studied in terms of their regulation of immune
responses. PAR-specific activities have been described in both
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eosinophils, basophils, monocytes, dendritic cells and T cells (see
[12] for review). For example, mast cell tryptase, known to activate
PAR2, promotes synthesis and release of pro-inflammatory
cytokines from peripheral blood mononuclear cells [13]. PAR1
and -2 activation in monocytes and dendritic cells results in
increased GM-CSF and IL-6, but reduced IL-4 [14,15,16]. In T
and B cells, PAR1 activation promotes proliferation and augments
T cell CD3 and IL-2 responses [17]. Studies using PAR deficient
mice indicate a duality of PAR function depending on the context
with both pro- and anti-inflammatory roles being reported. For
example, in rodents PAR1 has been shown to play an anti-
inflammatory role in cases of H. pylori induced gastritis [18], but
exacerbates inflammation in a murine model of colitis [19],
crescentic glomerulonephritis [20], and BSA induced arthritis
[21]. PAR2 has been demonstrated to play an anti-inflammatory
role in airways [22] and intestine [19], but a role in disease
exacerbation in adjuvant induced arthritis [23], allergic dermatitis
[24] and in EAE [25].
Given the abundant expression of KLK6 by T cells and
monocytes at sites of CNS inflammation, in the serum of patients
with secondary progressive MS, and its regulation by immune cell
activation, determination the likely role(s) of this unique serine
protease in immune function is long overdue. Herein we examine
the effect of KLK6 on lymphocyte survival and the possible role of
PAR1. Results indicate KLK6 promotes survival of murine
splenocytes by a mechanism that depends in part on activation
of PAR1 and which involves at least in part the up regulation of
pro-survival and down regulation pro-apoptotic Bcl-2 family
member signaling proteins.
Materials and Methods
Ethics Statement
All animal experiments were carried out with strict adherence to
NIH Guidelines for animal care and safety and were approved by
the Mayo Clinic Institutional Animal Care and Use Committee,
Animal Welfare Assurance number A3291-01, and Protocol
number A28508.
Model Systems
The effect of KLK6 on immune cell survival was examined
using whole splenocyte populations derived from C57BL6/J or
PAR1 deficient mice or the Jurkat T-leukemic cell line (clone E6-1,
TIB-152 American Type Culture Collection). Eight to 12 week old
C57 mice were obtained from Jackson Laboratories. Mice
deficient in PAR1
2/2 (B6.129S4-F2r
tm1Ajc/J) were also obtained
from Jackson and backcrossed to C57BL6/J for 10 generations,
such that C57 mice served as wild type controls in each
experiment. All animal experiments were carried out with strict
adherence to NIH Guidelines for animal care and safety and were
approved by the Mayo Clinic Institutional Animal Care and Use
Committee.
Cell Culture
Spleens were homogenized in RPMI-1640, red blood cells lysed
with ammonium chloride buffer, and splenocytes cultured in tissue
culture treated 96 well plates at a density of 7.5610
5 cells/ml. All
experiments were performed in serum free X-Vivo media (Lonza,
Mapleton, IL) containing 2 mM Glutamax, 1 mM sodium
pyruvate, 50 U/mL penicillin-streptomycin, 10 mM HEPES,
50 mM2 - b-mercaptoethanol and 10 mM non-essential amino
acids (Invitrogen). Jurkat T cells were maintained in log-phase
growth in the same defined media. All cells were maintained at
37uC in 95% air and 5% CO2. All culture conditions were
examined in triplicate within a given experiment and all
experiments repeated at least twice.
Reagents
Recombinant KLK1 and KLK6 were expressed using a
baculovirus/insect system, purified and activated as previously
described in detail [6,7,26]. We have developed expression systems
for both Homo sapiens and Rattus norvegicus KLK6 [6,7]. Phyloge-
netic analysis identifies Homo sapiens KLK6 and Rattus norvegicus
Klk6 as unambiguous orthologs [6]. In a pair-wise comparison of
the KLK6 proteins of these species there are no insertions or
deletions of amino acids. The mature proteins are 223 amino acids
in length in each case. The functional activity of Rattus norvegicus
and Homo sapiens KLK6 mature proteins can been directly
compared for digestions of myelin basic protein, laminin and
fibronectin and these show essentially identical specificities; and
the conservation of the regulatory autolytic inactivation property
for each protein has also been demonstrated [6,7]. The
characteristic preference for arginine versus lysine in the substrate
P1 position has also been directly compared between Rattus
norvegicus and Homo sapiens KLK6 mature proteins using identical
tripeptide substrates and has been demonstrated to be highly-
conserved in these species orthologs. Mus musculus KLK6 contains
two additional amino acids at the C-terminus but since this is anti-
podal to the active site it would have no known effect upon
enzyme activity or specificity and therefore is predicted to be
identical in function to the human and rat forms. Thus, the
available evidence supports a highly-conserved sequence, func-
tional activity, and substrate specificity between mouse, rat and
human KLK6 orthologs. The primary observation in this report,
that KLK6 improves survival of murine splenocytes and the
human Jurkat T cell line, has been observed in experiments which
utilized either the Rattus norvegicus or Homo sapiens forms of KLK6,
and all experiments shown were carried out using Rattus norvegicus
KLK6. All experiments involving KLK1 utilized highly purified
recombinant Homo sapiens KLK1 [26]. Use of Homo sapiens KLK1
to study physiological effects in a murine system has been
previously validated [27]. The functional activity of recombinant
KLKs were examined at concentrations ranging from 1 to 10 mg/
ml (40 to 400 nM) which correspond to concentrations that our
prior studies have shown induce intracellular signaling [11]. The
concentrations of KLK6 examined also encompass the physiologic
level seen in normal cerebrospinal fluid (0.5–2 mg/ml) [28,29,30]
and up to 5-fold excess, which we anticipate partially models the
elevated levels seen at sites of CNS inflammation in MS and its
animal models [1,2,3,4].
KLK6-Over Expression
Results demonstrated using recombinant KLK6 were con-
firmed in Jurkat T cells using a KLK6 over expression system.
Jurkat T cells were transduced with a vector in which the Homo
sapiens KLK6 gene (NM_002774) is under the control of a
cytomegalovirus (CMV) promoter (GeneCopoeia, Inc., Rockville,
MD), or the corresponding empty vector, by electroporation using
a Genetronics BTX T820 square-wave electroporator (San Diego,
CA). Stably transduced Jurkat cells were selected using 0.4 mg/ml
G418 (Invitrogen, Carlsbad, CA). All experiments described were
carried out in serum free X-Vivo media without the addition of
G418. Levels of KLK6 over expression in stable cell lines were
quantified by real time PCR as previously described in detail [3].
Briefly, total RNA was extracted from G418-selected Jurkat cells
transduced with KLK6-CMV, or vector alone, using RNA STAT-
60 (Tel-Test, Inc. Friendswood, TX) and 0.5 mg of total RNA
KLK6 Mediated Splenocyte and Jurkat Survival
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SYBR Green I (Roche Diagnostics, Mannheim, Germany) and an
i-Cycler IQ Real-Time PCR instrument (BioRad, Hercules, CA).
KLK6 expression levels were normalized to those for glyceralde-
hyde phosphate 3-dehydrogenase (GAPDH). Forward and reverse
primers for Homo sapiens KLK6 were Forward, 59-TGCCAG-
GGTGATTCTGGG-39 and Reverse 59-TGCAGACGTTGGT-
GTAGACT-39; and for GAPDH were Forward 59-ACCAC-
CATGGAGAAGGC-39 and Reverse 59-GGCATGGACTGTG-
GTCATGA-39. Expression levels in each case were quantified
relative to standard curves resulting from amplification of KLK6
or GAPDH nucleic acid templates.
Cell Death Paradigms
To determine the scope of action of KLK6 in altering immune
cell survival we examined its effects in a range of cell death
paradigms, including those mediated by transmembrane death
receptors, such as the Fas receptor (extrinsic pathway), and those
which result from cellular stress and activation of intracellular
mitochondrial signaling cascades (intrinsic pathways)[31]. Signal-
ing through the Fas receptor is known to directly activate apoptosis
by recruitment and activation of caspase enzymes [32] and was
induced in the present study using Fas ligand/TNFSF6 (2 mg/ml)
cross linked with anti-polyHistidine (10 mg/ml). Several activators
of intrinsic apoptotic mechanisms were also examined, including
spontaneous (resting) cell death, known to occur after harvest and
plating of splenocytes in vitro [33] and staurosporine-induced cell
death (0.1 to 1 mM), which occurs by broad spectrum protein
kinase inhibition [34,35]. Other activators of intrinsic apoptotic
mechanisms were also examined such as the glucocorticoid
dexamethasone (0.1 mM), which is widely used as an anti-
inflammatory and T cell apoptotic agent [36,37] and the
topoisomerase inhibitor camptothecin (1.0 mM), which was
originally developed as an anti-cancer therapeutic. Concanavalin
A (ConA, 5 mg/ml) is a lectin and well known lymphocyte mitogen
that promotes activation induced cell death [38]. Since campto-
thecin-induced lymphocyte apoptosis is enhanced in the presence
of mitogens [39], we examined the effects of KLK6 on cell death
induced by either camptothecin or ConA alone, or in combina-
tion. All agents utilized to induce cell death were obtained from
Sigma and were either applied to cultures at the time of cell plating
simultaneously with KLK6, or after cultures had first been pre-
incubated with KLK6 for 2 hr.
Flow Cytometry
Following experimental incubation periods which ranged from
4 to 72 hr, cells were harvested and stained with combinations of
antibodies recognizing to CD45, CD3, B220 or the early apoptotic
marker Annexin-V, conjugated to FITC, PE, or APC (e-
Bioscience, San Diego, CA). In each case, either propidium iodide
(PI) or 7-Aminoactinomycin D (7AAD) were used to label dead
cells (Sigma). Examination of the composition of the splenocyte
cultures examined revealed them to be predominantly lympho-
cytes with 24% being CD3
+ T lymphocytes and 60% being B220
+
B lymphocytes, while less than 2.5% were CD11b
+ monocytes.
Cells were analyzed by flow cytometry using a FACSCalibur flow
cytometer (BD Biosciences, Mountain View, CA). Live immune
cells were defined as those which were positive for the common
leukocyte antigen CD45, but negative for PI. Early and late
apoptotic/dead cells were distinguished using a combination of
AnnexinV-Phycoerythrin (PE) and 7AAD or AnnexinV-Fluores-
cein isothiocyanate (FITC) and PI (BD Biosciences). FlowJo
software (Ashland, OR) was used to quantify different cell
populations in flow cytometry experiments. Potential effects on
cell proliferation were examined by labeling cells with carboxy-
fluorescein succinimidyl ester [40,41] (CFSE, Invitrogen, Carls-
bad, CA) prior to plating followed by analysis using the FlowJo
proliferation platform at the completion of each experiment.
To compare multiple cell culture conditions within a given
experiment, the mean and standard error (SEM) across experi-
mental groups were analyzed by One-Way Analysis of Variance
(ANOVA) followed by Student-Newman-Keuls (SNK) post hoc
test except when data were not normally distributed when
ANOVA on Ranks and Mann-Whitney-U analyses were per-
formed. Statistical differences between two groups were compared
using the Student’s t-test or the Rank Sum test when data were
non-linear. P,0.05 was considered statistically significant. All
samples were analyzed in triplicate and experiments repeated at
least 3 separate times, using independent cell culture preparations,
with parallel results.
Western Blot Analysis
Protein lysates from whole splenocyte cell cultures were
separated on SDS-polyacrylaminde gels prior to transfer to
nitrocellulose membranes. Antibodies to detect Bcl-XL and Bim
were obtained from Cell Signaling Technology (Danvers, MA).
The Poly ADP-ribose polymerase (PARP) antibody was a kind gift
from Dr. S. Kauffman [42]. Equal loading was verified by re-
probing blots for b-Actin (Novus, Littleton, CO). In all cases
proteins of interest were detected on film using chemiluminescence
Supersignal (Pierce, Rockford, IL). For quantification, films were
scanned and images quantified using Image Lab 2.0 software
(BioRad). Relative changes in BIM and BCL-XL protein levels in
resting or treated cells were determined by normalizing optical
density measurements for either protein with those for Actin
detected on the same membrane. In the case of PARP, in which
level of cleavage was the end point of interest, both the upper band
corresponding to 116 kDa intact form, and the signature 89-kDa
caspase-generated fragment [43] were each normalized to Actin.
The percent PARP cleavage was then determined by calculating
the percent that the 89-kDa fragment was of the total PARP
(116+89 kDa fragments) detected. All Western blots were repeated
at least twice using separate cell culture preparations with similar
results.
Results
KLK6 differentially affects immune cell survival and
proliferation
As a first approach to define the possible immunological actions
of KLK6, its effects on survival and proliferation of murine
splenocytes were examined and compared to another kallikrein
family member, KLK1. While KLK6 did not significantly alter
splenocyte proliferation after 24 or 72 hr, it did promote a
substantial and dose dependent reduction in the number of cells
positive for markers of cell death across the same time points
(Fig. 1, see also Figs. 2, 3, 4, 5, 6, 7, 8). Significant reductions in the
number of PI positive dead cells were observed under resting
conditions when splenocytes were cultured in the presence of
either 1 or 10 mg/ml of KLK6 at the time of plating. Since 10 mg/
ml of KLK6 generated the most robust rescue this concentration
was carried forward in all subsequent experiments. Also, KLK6
promoted cell survival at both 24 and 72 hr time points such that
most subsequent experiments were carried out to 24 hr. Parallel
examination of a second kallikrein, KLK1, generated by
baculoviurs expression in parallel with KLK6 [26], did not
significantly impact cell survival. KLK1 (10 mg/ml) did however
promote a significant increase in the percent of divided cells when
KLK6 Mediated Splenocyte and Jurkat Survival
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proliferation were not seen at lower concentrations of KLK1, or
when cells were examined at 72 hr. The significance of KLK1’s
mitogenic effects toward splenocytes will need to be followed up in
future studies. The general lack of KLK6-induced proliferative
effects support the hypothesis that overall changes in splenocyte
survival and death observed across experiments were not due to
KLK6-mediated changes in cell proliferation.
KLK6 promotes survival of T cells and B cells across
multiple cell death paradigms
To determine whether promotion of lymphocyte survival
represents a fundamental feature of KLK6 biology, we examined
its ability to reduce cell death across a range of paradigms. KLK6
not only reduced the death of splenocytes which occurs after
explant and culture (Resting, Figs. 1, 2, 3, 4, 5, 6, 7), but also that
seen in response to 0.1 mM dexamethasone (Figs. 2, 3, 7). KLK6
also reduced the death of splenocytes induced by 1 mM
staurosporine (Fig. 5) and in response to 2 mg/ml Fas ligand
(Fig. 2). Co-labeling of splenocytes with CD3 to label T
lymphocytes, and B220 to label B lymphocytes, in conjunction
with 7AAD to identify cell death, indicated that KLK6 reduced
the number of dead cells in both populations in resting cultures
and in response to dexamethasone (Fig. 7). Parallel to observations
using mixed splenocyte preparations, and supporting strong
KLK6-mediated effects toward T lymphocytes, recombinant
KLK6 also significantly diminished Jurkat T cell death under
resting conditions and when exposed to 1 mM camptothecin or
1 mM camptothecin plus 5 mg/ml ConA, and in response to Fas
ligand receptor cross linking (Figs. 2, 4). The ability of KLK6 to
rescue splenocytes or Jurkat T cells across cell death paradigms
was consistently observed when KLK6 was applied simultaneously
with death inducing agents. A two hour pre-incubation with
KLK6 prior to dexamethasone application was shown to result in
a small but statistically significant enhancement of survival (Fig. 2,
P,0.05).
To determine whether prolonged or continual exposure to
KLK6 was necessary to promote significant rescue effects, we
compared the pro-survival effects of abbreviated periods of KLK6
stimulation (Fig. 3). Interestingly, the pro-survival effects of KLK6
over a 24 hr period under resting conditions or in the presence of
dexamethasone were similar when whole splenocyte cultures were
treated with KLK6 for 5, 30 or 60 min, or for the full 24 hr period
of culture. However when experimental endpoints were extended
to 48 hr, only continual treatment with KLK6, but not transient
exposure up to 60 min, was sufficient to promote more prolonged
pro-survival effects.
In addition to examination of the effects of recombinant KLK6,
we additionally determined whether over expression of the KLK6
gene in the Jurkat T cell line would similarly alter the extent of cell
death observed (Fig. 6). Jurkat cells were stably transduced with a
vector in which the KLK6 gene is constitutively expressed under
control of the CMV promoter, or empty vector, and KLK6
expression levels quantified by real time PCR [3]. Similar to
KLK6 transcript levels we have previously reported in Jurkat T
cells, mean KLK6 transcript levels (6 SEM) were 5.5E+05
62.5E+04 in cells transduced with vector alone and 2.65E+07 6
1.0E+04 in KLK6-CMV transduced cells. GAPDH transcript
levels in the same samples were 4.0E+06 6 1.7E+05 and 3.9E+06
6 1.8E+05, respectively, demonstrating equal RNA loading. This
Figure 1. Differential effects of KLK1 and KLK6 on survival and proliferation of murine splenocytes. To differentiate between possible
effects of KLK6 on cell survival versus proliferation, murine splenocytes were labeled with CFSE and cultured in defined media in the presence of 1 or
10 mg/ml of KLK1, KLK6, or vehicle alone (Control), for periods of 24 or 72 hr. At harvest dead cells were labeled using PI and samples were examined
by flow cytometry. A, Stimulation of cultures with either 1 or 10 mg/ml of KLK6, but not KLK1, significantly reduced the number of dead (PI
+) cells
observed at either the 24 or 72 hr time points (72 hr shown, B). The intensity of CFSE labeling in PI
- cells was determined using the proliferation
platform of the Flow Jo Program and labeling peaks observed after 24 hr are shown in (C). KLK1 (10 mg/ml), but not KLK6 promoted a significant
increase in the percent of cells divided at the 24 hr time point (D); Data are expressed as mean 6 SEM, One Way ANOVA with SNK post hoc test;
P,0.001**, P,0.02*. (SSC, side scatter). Parallel observations have been made in a least three separate cell culture experiments.
doi:10.1371/journal.pone.0018376.g001
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replicated by PCR more than 3 times using separate cell culture
preparations. Importantly, relative to cells transduced with vector
alone, those transduced with the KLK6-CMV vector showed a
significant increase in the number of live cells (7AAD
2, Annexin
V
-), and a decrease in the number of dead cells (7AAD
+) under
resting conditions, and when challenged with 0.1 or 0.25 mM
staurosporine (Fig. 6).
KLK6 affects the apoptotic cascade
The ability of KLK6 to specifically affect apoptosis in
splenocytes and Jurkat T cells was assessed by comparing
KLK6-induced changes in the relative percentage of live cells
(AnnexinV
-,P I
2), early apoptotic cells (AnnexinV
+,P I
2), and
dead cells (AnnexinV
+,P I
+) across several cell death paradigms
(Figs. 4, 5, 6). In some cases 7AAD was used in place of PI.
In the case of Jurkat T cells under resting conditions,
recombinant KLK6 promoted a reduction in the number of dead
cells and a corresponding increase in the number of live cells, but
did not significantly alter the number of early apoptotic cells when
examined at 4, 24 or 48 hr post plating (Fig. 4). When Jurkat cells
were challenged with the topoisomerase inhibitor camptothecin,
with ConA, or a combination of these agents, KLK6 reduced the
number of dead cells at the 4, 24 and 48 hr time points examined,
mirroring observations under resting conditions. A significant
increase in the number of live cells was also seen in each
circumstance except after 48 hr exposure to the Camptothecin or
the ConA+Camptothecin combination. Interestingly, Jurkat cells
cultured in the presence of KLK6 in addition to ConA, or ConA
plus camptothecin, showed an accumulation of cells at early
apoptotic stages at the 24 hr time point examined. By 48 hr,
KLK6-induced accumulation of early apoptotic cells was seen
Figure 2. KLK6 decreases death of murine splenocytes and Jurkat T cells across multiple paradigms. KLK6 (10 mg/ml) significantly
reduced the number of PI
+ dead splenocytes observed by flow cytometry after a 24 hr period in culture under resting conditions, in response to
(0.1 mM) dexamethasone (A), or after 24 hr exposure to Fas ligand (FasL, 2 mg/ml, B). In parallel experiments (C), Jurkat T cells showed significantly
reduced levels of cell death under resting conditions and in response to camptothecin (1.0 mM), or Fas ligand (C, 2 mg/ml) when co-treated with KLK6
(10 mg/ml). Fas ligand at 2 mg/ml caused greater cell death in Jurkat cells (C) relative to splenocytes (B) under the conditions of this study. KLK6 was
applied at the time of plating in conjunction with cell death inducing agents in each case. A small but significant improvement in the ability of KLK6
to rescue splenocytes from death was seen with a 2 hr pre-incubation prior to the addition of dexamethasone (A); Data are expressed as mean 6 SEM
of triplicate cultures examined in parallel, One Way ANOVA with SNK post hoc test for multiple comparisons in (A), two-way comparisons A to C, were
made using Students t-test; P,0.001***, P#0.005**, P#0.02*. All results shown are representative of at least 3 independent cell culture experiments.
doi:10.1371/journal.pone.0018376.g002
Figure 3. As little as a 5 minute pulse of KLK6 is sufficient to promote splenocyte survival. To gauge the minimal time of exposure to
KLK6 necessary to observe its pro-survival effects, splenocytes were pulsed with KLK6 (10 mg/ml) for periods of 5, 30 or 60 min, or in the presence of
KLK6 for the full 24 or 48 hr period of culture examined, prior to labeling with PI for analysis of dead cells by flow cytometry (A and B). A 5 min pulse
with KLK6 promoted significant survival of explanted resting splenocytes over a 24 hr culture period that was similar in magnitude to that seen with
longer pulses, i.e. 30 or 60 min and 24 hr (A). A 5 min pulse with KLK6 was also sufficient to promote survival when cells were exposed to
dexamethasone (0.1 mM) for 24 hr (C). After longer periods of culture however (B, 48 hr), only more the more prolonged period of KLK6 stimulation
(48 hr) exerted significant pro-survival effects (B). Data shown are the mean 6 SEM of triplicate cell culture samples run in parallel and examined by
One Way ANOVA with the SNK post hoc test for multiple comparisons; P,0.001**, P#0.005*. Results shown are representative of at least 3 separate
experiments using independent cell culture preparations.
doi:10.1371/journal.pone.0018376.g003
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alone. Supporting the concept that KLK6 is able to delay
apoptosis under certain conditions, KLK6-CMV over expression
in Jurkat cells was also associated with not only an increase in the
number of live cells and a decrease in the overall number of dead
cells, but in the presence of 0.25 mM staurosprorine, a significant
accumulation of AnnexinV
+, 7AAD
2) early apoptotic cells was
also observed (Fig. 6).
Examination of live, early apoptotic, and dead cells in murine
splenocyte cultures generated results parallel to those observed in
Jurkat T cells, that is KLK6-induced decreases in the percentage
of dead cells was accompanied by increases in the number of cells
in the live and/or early apoptotic populations depending on the
conditions examined (Fig. 5). Under resting conditions over 24 hr,
the presence of KLK6 significantly reduced the number of dead
cells with a corresponding increase in the live population, while the
number of early apoptotic cells was largely unchanged. In the
presence of dexamethasone (0.1 mM), or staurosporine (1 mM), co-
exposure to KLK6 promoted a significant decrease in the number
of dead cells and a small but significant increase in the live cell
Figure 4. KLK6 promotes survival of Jurkat T cells in part by slowing the apoptotic cascade. To address the effect of KLK6 on apoptosis,
Jurkat T cells were grown under resting conditions (A), or in the presence of apoptosis inducing agents (B to D), then labeled with Annexin V-PE and
7AAD prior to flow cytometry. Under resting conditions (A), and in the presence of camptothecin (B, 1.0 mM), ConA (C, 5 mg/ml), or ConA plus
camptothecin (D), KLK6 (10 mg/ml) promoted an increase in the percentage of live cells (unlabeled) and a decrease in the percentage of dead cells
(Annexin V
+ and 7AAD
+) at both acute (4 hr), subacute (24 hr), and in some cases the more chronic time point examined (48 hr). Interestingly, in the
presence of apoptosis inducing agents (B to D), KLK6 also promoted a corresponding increase in the percentage of Jurkat T cells positive for Annexin
V, but negative for 7AAD, and therefore classified as in the early stages of apoptosis. These results suggest KLK6 may delay but not block the
apoptotic cascade. Data shown are for triplicate cultures examined in parallel and are expressed as mean 6 SEM, One Way ANOVA with SNK post hoc
test for multiple comparisons; P,0.001***, P#0.005**, P#0.02*. All results shown are representative of those seen across at least three experiments
using independent cell culture preparations.
doi:10.1371/journal.pone.0018376.g004
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exposure to KLK6 also resulted in a significant accumulation of
cells at the early apoptotic stage.
KLK6-mediated lymphocyte survival occurs in T cells and
B cells and depends in part on activation of PAR1
To investigate the pro-survival effects mediated by KLK6
toward splenic lymphocytes, and the potential involvement of
PAR1, we examined the ability of KLK6 to alter resting or
dexamethasone-induced death in whole splenocyte cultures
isolated from WT or PAR1 knockout mice and used flow
cytometry approaches to specifically examine the response of T
and B cell subsets (Fig. 7). The overall extent of cell death (see also
Figs. 1, 2, 3, 5), in addition to that occurring specifically in splenic
CD3
+ T cells, and B220
+ B cells, was examined. Basal levels of cell
death were not observed to differ significantly between WT and
PAR1
2/2 mice. Under resting conditions, the absence of PAR1
completely blocked the ability of KLK6 to support the survival of
splenocytes overall, and in either of the CD3
+ T cell or B220
+ B
cell subsets. In the case of dexamethasone treatment of WT
splenocytes, KLK6 was seen to significantly reduce overall cell
death and that observed in both CD3
+ T cells and B220
+ B cells.
In splenocytes isolated from PAR1
2/2 mice, KLK6 was no longer
able to significantly decrease dexamethasone induced CD3
+ T cell
death, although overall cell death and that of B220
+ B cells
continued to be significantly reduced by KLK6.
The ability of KLK6 to alter apoptosis was further addressed by
examining its effects on cleavage of PARP, one of the final caspase
substrates cleaved in the apoptotic cascade, in whole splenocyte
preparations under resting conditions or when treated with
camptothecin or ConA (Fig. 8A). Significant levels of cleaved
PARP were detected in WT splenocytes grown under resting
conditions and when exposed to camptothecin for 24 hr. In each
case, co-treatment with KLK6 significantly reduced the amount of
cleaved PARP detected by Western blot.
KLK6 differentially regulates Bcl-2 family member
signaling
To begin to address the mechanism by which KLK6 may
promote splenocyte survival we examined its effects on Bcl-2
family pro- and anti-apoptotic signaling cascades. Levels of the
pro-survival protein Bcl-XL in resting, camptothecin or ConA
treated whole splenocyte cultures were below the detection limit of
our assay. When splenocytes were exposed to either camptothecin
or ConA in the presence of KLK6 however, significant elevations
in Bcl-XL were observed (Fig. 8B). KLK6 did not elevate Bcl-XL
protein levels in resting splenocyte cultures. Interestingly, KLK6
reduced levels of the pro-apoptotic protein BIM, under resting
conditions and in the presence of camptothecin or ConA (Fig. 8B).
Discussion
KLK6 levels are elevated at sites of inflammation in active MS
lesions, in CNS trauma, and in animal models of these pathologies
[1,46]. Elevations are due in part to expression of KLK6 by
infiltrating immune cells [1,5,46], yet very little is currently known
Figure 5. The ability of KLK6 to decrease death of murine splenocytes relates to its ability to delay the apoptotic cascade. (A)
Histogram and corresponding dot plots (B) demonstrate that KLK6 significantly reduced the percentage of dead cells (Annexin V-FITC
+ and PI
+)
observed in cultures of splenocytes under resting conditions and after exposure to dexamethasone (0.1 mM), or staurosporine (1 mM). Reduced cell
death was accompanied by a significant increase in the live population (unlabeled cells) under resting conditions and with exposure to staurosporine.
KLK6 exposure also resulted in a corresponding increase in the percentage of early apoptotic cells (Annexin V-FITC
+,P I
-) in the presence of apoptosis
inducing agents. Data shown are the mean 6 SEM of triplicate cultures examined in parallel; One Way ANOVA with SNK post hoc test for multiple
comparisons, P,0.001***, P,0.003**, P,0.007*. All results shown are representative of that seen in at least 3 independent experiments.
doi:10.1371/journal.pone.0018376.g005
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KLK6 gene is constitutively expressed under the control of a CMV promoter, or with an empty vector (Control), and levels of live (Annexin V-PE
- and
7AAD
2), early apoptotic (Annexin V-PE
+ and 7AAD
2), or dead (Annexin V-PE
+ and 7AAD
+) cells determined by flow cytometry under resting
conditions, or after 24 hr periods of exposure to 0.1 or 0.25 mM staurosporine. (A) Histogram and corresponding dot plots (B), demonstrate KLK6 over
expression produces effects largely parallel to those afforded by treatment of cultures with recombinant KLK6. There was a decrease in the
percentage of dead cells and an increase in the number of live cells in Jurkat T cells over expressing KLK6, relative to those expressing an empty
vector. KLK6 over expression also reduced cell death in the presence of 0.1 or 0.25 mM stuarosporine relative to that seen in cells stably transduced
with empty vector. Reductions in cell death were likely to reflect in part a delay in apoptosis, since after 24 hr exposure to 0.25 mM Staurosporine,
KLK6 over expression not only reduced the number of dead cells and increased the number of live cells, but cells in the early stages of apoptosis
(AnnV-PE
+, 7AAD
2) were also significantly elevated. Data are expressed as mean 6 SEM of triplicate cultures examined in parallel; One Way ANOVA
with SNK post hoc test for multiple comparisons, P,0.001***, P=0.002**, P=0.003*. All data shown is representative of that seen in at least 3
independent cell culture experiments.
doi:10.1371/journal.pone.0018376.g006
Figure 7. The ability of KLK6 to reduce murine T and B cell death depends in part on activation of PAR1. To determine the involvement
of PAR1 in KLK6-mediated reductions in lymphocyte death, the ability of KLK6 (10 mg/ml) to reduce cell death under resting conditions, or in
response to dexamethasone (0.1 uM), was compared between wild type and PAR1
2/2 splenocytes. Comparisons were made between the total
percentage of 7AAD
+ dead cells, or between those additionally labeled to recognize CD3
+ T cells, or B220
+ B cells. (A) KLK6 (10 mg/ml) significantly
reduced the overall percentage of 7AAD
+ dead cells under resting conditions and in response to dexamethasone (0.1 mM). KLK6-mediated reductions
in overall cell death in both paradigms (A) were seen to encompass both CD3
+ T lymphocytes (B) and B220
+ B lymphocytes (C). The absence of PAR1
(PAR1 KO) impaired the ability of KLK6 to significantly reduce the overall percentage of cell death and that associated with T cells and B cells under
resting conditions. The absence of PAR1 also impaired the ability of KLK6 to reduce dexamethasone-induced CD3
+ T cell death. Data shown are mean
6 SEM of triplicate cultures examined in parallel; One Way ANOVA with SNK post hoc test for multiple comparisons, P=0.002***, P#0.003**,
P,0.05*. Results shown are representative of that seen in at least 3 independent experiments.
doi:10.1371/journal.pone.0018376.g007
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immune function. In this study, we demonstrate that KLK6 exerts
pro-survival effects toward murine splenocytes and Jurkat T cells
across a range of cell death paradigms. We further demonstrate
that the pro-survival effects of KLK6 in splenocytes depend in part
on activation of the G-protein coupled receptor, PAR1, and
involve at least a subset of Bcl-2 family member signaling cascades.
Taken together, these findings delineate KLK6 as a new player
within the network of regulatory mechanisms that govern survival
of immune cells.
The present studies demonstrate for the first time that KLK6 is
able to promote survival of murine splenocytes as well as the
human leukemic Jurkat T cell line across divergent cell death
paradigms encompassing both the intrinsic/mitochondrial and the
extrinsic Fas-Fas ligand-induced apoptotic signaling pathways.
The ability of KLK6 to promote survival of T-lymphocytes is
supported by observations of its pro-survival effects toward both
Jurkat T cells and CD3 positive cells in whole splenocyte cultures.
Notably, we were able to demonstrate robust pro-survival effects of
KLK6 toward Jurkat T cells when cells were either treated with
recombinant KLK6 or when KLK6 over expression was enforced
using a KLK6 expression construct under control of a CMV
promoter. The likely fundamental role of KLK6 in lymphocyte
survival in general is supported by findings in whole splenocyte
cultures that pro-survival effects extend also to B220 positive B-
lymphocytes. Contrasting its robust pro-survival effects, KLK6 did
not significantly alter splenocyte proliferation under the conditions
of this study, indicating that proliferative effects were unlikely to
account for its ability to increase the number of viable cells.
Interestingly, another member of the KLK family, KLK1, better
known as true tissue kallikrein, did exert proliferative effects
toward splenocytes in the first 24 hr period of culture. Taken with
evidence that both KLK1 and KLK6 are elevated in the serum of
MS patients [4], it is tempting to speculate that these proteases
may operate in tandem to support inflammation by uniquely
enhancing immune cell survival and proliferation.
Experiments examining Annexin V labeling, which is taken as a
marker of the early stages of apoptosis, in conjunction with
markers of plasma membrane permeabilization, such as PI or
7AAD that are indicative of cell death, suggest KLK6 is capable of
delaying the cell death cascade at early stages of apoptosis. While
KLK6 increased the number of live cells and decreased the
detection of dead cells across a range of cell death paradigms, both
in whole splenocyte preparations and in the case of Jurkat T cells,
KLK6 also promoted a significant accumulation of cells at the
early stages of apoptosis (Annexin V
+,P I
2). The accumulation of
Annexin V positive cells accompanied by a decrease in dead cells
was particularly prominent in Camptothecin and ConA treated
Jurkat cells carried out to the 48 hr time point. These data favor a
model whereby KLK6 delays the apoptotic process. Taken with
findings herein that KLK6 also blocks the cleavage of PARP, it is
likely that KLK6 delays the apoptotic cascade from entering into
the effector phase when caspase 3 activation and PARP cleavage
occur.
The mechanism by which KLK6 promotes lymphocyte survival
was shown to involve, at least in part, activation of the thrombin
receptor PAR1. Using genetically PAR1 deficient mice the present
studies demonstrate that the absence of PAR1 completely blocks
the ability of KLK6 to reduce the final stages of death of T- and B-
lymphocytes under resting conditions. While there is growing
evidence regarding the role of PAR activation in inflammation
[47,48], particularly with regard to roles in driving cytokine
production and proliferation, this is the first report of the likely
involvement of PAR1 activation in the control of lymphocyte
survival. Of interest in this regard, several recent studies have
demonstrated a role for PAR1 in survival of non-immune cells
including, prostate cancer cells via NFKB and activation of Bcl-XL
[49], breast cancer cells via activation of AKT [50], CC139
fibroblasts by suppression of Bim [51], and rat astrocytes by
release of chemokine growth-regulated oncogene/cytokine-in-
duced neutrophil chemoattractant-1 [52]. The present in vitro
results suggest that the anti-inflammatory effects of PAR1
deficiency, already described in some murine models, may relate
in part to the absence of pro-survival signaling mediated by certain
agonists such as KLK6 at this receptor, and therefore increased
vulnerability of lymphocytes to apoptosis. For example, PAR1
deficiency has been associated with attenuated inflammatory
responses in murine crescentic glomerulonephritis [20], colitis
[19], and BSA-induced arthritis [21]. Treatment of mice with the
thrombin inhibitor hirudin, also blocks inflammation in crescentic
glomerulonephritis and in addition was recently shown to
attenuate disease severity in EAE [53].
The absence of PAR1 had less effect on the ability of KLK6 to
promote overall splenocyte survival, or that of B lymphocytes in
the presence of dexamethasone compared to cells under resting
conditions, although its absence did significantly reduce KLK6-
mediated survival of CD3
+ T lymphocytes. These differential
effects depending on the cell death paradigm examined suggest the
Figure 8. KLK6 differentially regulates PARP cleavage and Bcl-2
family member protein levels. Western blots illustrate KLK6 (10 mg/
ml)-induced changes in the amount of cleaved PARP (116 kDa intact
form, 89-kDa fragment, A), or in levels of Bcl-2 family members (B),
observed in murine splenocytes derived from WT mice and cultured for
a 24 hr period under resting conditions, or in the presence of
camptothecin (1.0 mM), or ConA (5 mg/ml). Relative to non-KLK6-treated
control samples, KLK6-treatment promoted reductions in PARP
cleavage in WT resting (98% reduction) and camptothecin (89%
reduction) co-treated cultures (A). Significant PARP cleavage was not
seen with ConA treatment at the 24 hr time point examined. B, The pro-
survival protein Bcl-XL was elevated in cultures exposed to campto-
thecin or ConA when co-treated with KLK6. Relative to non-KLK6
treated sister wells, detection of Bcl-XL was elevated by 40-fold in the
presence of KLK6+camptothecin and 80-fold in the presence of
ConA+KLK6. KLK6-induced changes in Bcl-XL were not seen in resting
cultures. KLK6 suppressed detection of the pro-apoptotic protein Bim
by 83 and 84% in resting and Con A treated cultures respectively, and
by 16% in cultures treated with camptothecin. Actin was used to
control for loading in each case. All Western blots shown are
representative of from 2–5 separate cell culture experiments.
doi:10.1371/journal.pone.0018376.g008
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nisms when cells are under stress and that these may additionally
be cell type specific. Given our prior studies that show KLK6 is
also capable of activating PAR2 [8,9,10,11], as well as bradykinin
receptor 2 [11], it is highly possible that KLK6-mediated pro-
survival effects occur by activation of multiple receptors thereby
triggering signaling cascades that combine to overcome or delay
death signaling cascades. In this way, the ability of KLK6 to
regulate survival of T and B cells would be sharply tuned by
differential expression of receptors activated by KLK6 in response
to changing environmental cues.
That KLK6-mediates its pro-survival effects in a receptor
dependent fashion is also supported by observations herein which
show as little as 5 min exposure to KLK6 was sufficient to drive
survival in the short term (i.e. 24 hr). Of interest in this regard,
only continual KLK6 exposure, but not short pulses up to 60 min
in duration, were able to delay cell death over more prolonged
culture periods.
KLK6 was shown to affect the balance of pro- and anti-
apoptotic members of the Bcl-2 family. In whole splenocyte
populations challenged with camptothecin or ConA, KLK6 up
regulated the pro-survival protein Bcl-XL and suppressed levels of
the pro-apoptotic BH3 only family member Bim. Interestingly,
while KLK6 suppressed Bim in whole splenocyte cultures under
all conditions examined, its ability to up regulate Bcl-XL was only
detected in cells undergoing an additional stress, such as
camptothecin or ConA, but not in resting cells. These results
support the concept that KLK6 promotes survival in part by the
integration of multiple signaling pathways, including those seen
only in the face of cellular stress. While much remains to be
learned regarding the signaling pathways triggered by KLK6 to
alter immune cell survival under different conditions, the ability of
KLK6 to strongly suppress Bim is of particular interest since this
BH3 only family member is known to play an essential role in
lymphoid and myeloid cell homeostasis [54], in the deletion of
autoreactive T [55] and B cells [56], in addition to the shut down
of acute T cell immune responses [33,57]. Given the elevated
levels of KLK6 in MS patient serum and in active MS lesions we
hypothesize one role may be to prolong inflammatory cell survival
by altering levels of Bcl-2-family members. The current findings
point to the need for additional studies to dissect the signaling
cascades elicited by KLK6 in different immune cell subsets and its
impact on their functional properties in vivo.
Collectively, these in vitro studies define KLK6 a possible new
participant in the molecular signaling cascades that regulate
immune cell life and death. Given the relatively widespread
distribution of KLK6 in human tissues [3,58,59], and increasing
awareness of its regulation in disease [1,4,28,58,60,61,62,63], this
novel enzyme is in a position to play an important regulatory role
in immune-related disorders, including but not limited to MS.
Since insufficient lymphocyte apoptosis is a well known participant
in autoimmune and lymphoproliferative disease, but in excess can
promote immunodeficiency, approaches that target KLK6 may
hold new promise for the treatment of diseases with an
inflammatory substrate.
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